colchicine
AssetAlso ColcrysTM, SAP-001, NSC-757, Colcrys
Inhibits microtubule polymerization by binding tubulin, disrupting inflammasome activation and neutrophil migration.
- Stage
- Approved
- Modality
- Small molecule
- Target
- NLRP3 inflammasome
- 12
- Indications
- 166
- Trials
- 2
- Developers
Indications
12Acute Gout
Approved, accessdata.fda.gov, 7 Oct 2026
Cardiovascular death
Approved, accessdata.fda.gov, 7 Oct 2026
Cardiovascular disease
Approved, accessdata.fda.gov, 7 Oct 2026
9 more
In the full profile
- Targets and what it contains4
- Owner and partners2
- Trials166
- Evidence for its targets5
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.